- Home
- EVT vs ANIP Comparison
EVT vs ANIP Comparison
Compare EVT & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVT
- ANIP
- Stock Information
- Founded
- EVT 2003
- ANIP 2001
- Country
- EVT United States
- ANIP United States
- Employees
- EVT N/A
- ANIP N/A
- Industry
- EVT Finance Companies
- ANIP Biotechnology: Pharmaceutical Preparations
- Sector
- EVT Finance
- ANIP Health Care
- Exchange
- EVT Nasdaq
- ANIP Nasdaq
- Market Cap
- EVT 1.7B
- ANIP 1.5B
- IPO Year
- EVT N/A
- ANIP N/A
- Fundamental
- Price
- EVT $23.21
- ANIP $58.72
- Analyst Decision
- EVT
- ANIP Strong Buy
- Analyst Count
- EVT 0
- ANIP 8
- Target Price
- EVT N/A
- ANIP $80.13
- AVG Volume (30 Days)
- EVT 140.9K
- ANIP 435.3K
- Earning Date
- EVT 01-01-0001
- ANIP 05-09-2025
- Dividend Yield
- EVT 8.50%
- ANIP N/A
- EPS Growth
- EVT N/A
- ANIP N/A
- EPS
- EVT 6.63
- ANIP N/A
- Revenue
- EVT $69,404,302.00
- ANIP $674,068,000.00
- Revenue This Year
- EVT N/A
- ANIP $29.87
- Revenue Next Year
- EVT N/A
- ANIP $7.53
- P/E Ratio
- EVT $3.51
- ANIP N/A
- Revenue Growth
- EVT N/A
- ANIP 30.27
- 52 Week Low
- EVT $19.20
- ANIP $52.50
- 52 Week High
- EVT $25.83
- ANIP $77.00
- Technical
- Relative Strength Index (RSI)
- EVT 55.70
- ANIP 35.30
- Support Level
- EVT $22.89
- ANIP $57.33
- Resistance Level
- EVT $23.29
- ANIP $59.06
- Average True Range (ATR)
- EVT 0.35
- ANIP 1.93
- MACD
- EVT -0.03
- ANIP -0.36
- Stochastic Oscillator
- EVT 54.12
- ANIP 18.39
About EVT Eaton Vance Tax Advantaged Dividend Income Fund of Beneficial Interest
EATON VANCE TAX ADVANTAGED DIVIDEND INCOME FUND is a diversified, closed-end management investment company. Its objective is to provide a high level of after-tax total return consisting mainly of tax-advantaged dividend income and capital appreciation. The fund pursues its objective by investing in dividend-paying common and preferred stocks. Its portfolio of investments consists of electric utilities, energy equipment and services, food products, health care providers and services, internet software and services, and other areas.
About ANIP ANI Pharmaceuticals Inc.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.